期刊文献+

换瓣术后华法林维持量与mEH ApoE基因多态性的相关性研究 被引量:2

下载PDF
导出
摘要 目的探讨mEH基因T612C、A691G位点sNP及ApoE基因型在中国汉族人群中的分布,并探讨华法林维持剂量与其相关性。方法共选取52例换瓣术后患者以及68例健康汉族个体。瓣膜置换术后个体根据国际化标准比值(INR)控制在1.5~2.2,调整华法林维持剂量,采用PCR-RFLP技术检测ApoE基因型、Pyrosequencing法检测mEHT612C及A691GSNP。结果(1)在120个受测试人群中,mEHT612C等位基因频率分别为74.6%和25.4%;而mEHA691G分别为66.7%、33.3%,换瓣人群中mEHT612C的纯合子比杂合子和野生型的所需华法林剂量要高,分别为(5.5±2.9)mg/d、(4.8±2.2)mg/d、(4.0±2.6)mg/d,三者之间剂量比较有显著性差异(P〈0.05)。(2)在120个受测试人群中,ApoE基因型等位基因E2,E3,E4的频率分别为44.2%、35.8%、20.O%;换瓣人群中各基因型所需华法林的剂量分别为(4.5±2.7)mg/d、(4.7±2.4)mg/d、(4.4±2.6)mg/d,三者之间差异无统计学意义(P〉0.05)。结论mEH基因T612C、A691G位点SNP能解释部分个体之间华法林维持剂量的差异,ApoE基因型的差异不能解释华法林维持剂量的差异。 Objective To explore the relationship between warfarin maintain dose with single nucleotide polymorphisms for gene mEH and genotype of ApoE, also to Discussion on the distribution of Chinese Hart population. Methods A total of 50 cases were selected after valve replacement patients and 50 cases of healthy Hart individuals. Warfarin maintain dose was adjusted to the low anticoagulant level in which the INR was between 1.5 and 2.2.The polymorphisms of ApoE was detected using PCR-RFLP method; single nucleotide polymorphisms on T612C and A691G for gene mEH was detected using pyrosequeneing method. Results 1. On the test group, Allele frequencies ofmEH on T612C were 71.2% and 28.8%; on A691G were 67.3% and 32.7%. Among valve replacement cases, Homozygotes of mEH T612C required higher warfarin dose than heterozygous and wild type, were 5.5±2.gmg, 4.8± 2.2mg, 4 ± 2.6rag/d, between the three doses had significant difference, (P〈0.05) . 2.On the test group, the ApoE genotype alleles E2, E3, E4 frequencies were 21%, 53%, 26%; Among valve replacement populations, required warfarin doses of different genotypes were 4.5 ± 2.7mg, 4.7± 2.4mg, 4.4 ±2.6rag/d, no significant difference were found, ( P〉0.05 ) . Conclusion Single nucleotide polymorphism on mEH T612C and A691G loci gene can explain part of individual difference on warfarin maintenance dose, but ApoE genotype difference can not explain the difference on warfarin maintenance dose.
出处 《浙江临床医学》 2012年第7期777-779,共3页 Zhejiang Clinical Medical Journal
基金 深圳市科技计划资助项目(编号201102149)
关键词 机械瓣膜置换术 mEH APOE 基因多态性 Mechanical heart valve prostheses, Implantation, mEH ApoE
  • 相关文献

参考文献9

  • 1Omiecimki CJ,Hassett C,Hosagrahara V. Epoxide hydrolase polymorphism and role in toxicology. Toxicol Lett 2000,(112-113):365-370.
  • 2Gsur A,Zidek T,Schnattinger K,Feik E,Haidinger G,Honaus P,et al. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. BrJ Cancer 2003,(89):702-706.
  • 3Cain D,Hutson SM,Wallin P.. Assembly of the warfarin sensitive vitamin K 2,3 epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 1997,(272):29068-29075.
  • 4Li T,Chang CY,Jin DY,Lin PJ,Khvorova A,Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004,(427):541-544.
  • 5Fakhrai-radh,Pourmandn,R.onaghim . Pyrosequencing: an accurate detection platform for single nucleotide polym orphisms.Hum M utat,2002,(19):479-486.
  • 6Cavallari LH,Langaee TY,Momary KM,Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010,87(4):459-464.
  • 7Wangl,Marincolafm. A plying pyrosequencing to H LA typing. A SH I Q uarterly,2003,(27):16-18.
  • 8Kimmel SE,Christie J,Kealey C,et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Phamlacogenomics J. 2008(1):53-60.
  • 9Ohno M,Yamamoto A,Ono A,et al.Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. EurJ C lin Pharmacol. 2009,65(11):1097-1103.

同被引文献29

  • 1许俊堂,胡大一.华法林的临床应用[J].中国医刊,2004,39(10):43-45. 被引量:63
  • 2Shearer MJ, Fu X, Booth SL. Vitamin K Nutrition, metabo- lism, and requirements: Current Concepts and future research [J]. Adv Nutr, 2012, 3(2):182-195.
  • 3Suriapranata IM, Tjong WY, Wang T, et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indone- sesians[J]. BMC Med Genet, 2011, 12:80.
  • 4Glurich I,Berg RL,Burmester JK.Does CALU SNP rs1043550 Contribute Variability to Therapeutic Warfarin Dosing Re-quirements?[J]. Clin Med Res, 2013, 11(2):73-79.
  • 5Lain MP, Cheung BM.The pharmacogenetics of the response to warfarin in Chinese[J]. Br J Clin Pharmacol, 2012, 73(3) : 340-347.
  • 6Shahin MH, Khalifa SI, Gong Y, et al. Genetic and non- ge- netic factors associated with warfarin dose requirements in Egyptian patients[J]. Pharmacogenet Genomics, 2011, 21 (3) :130-135.
  • 7Martin ER, Lai EH, Gilbert JR, et al. SNPing away at com- plex diseases: analysis of single-nucleotide polymorphisms a- round APOE in Alzheimer disease. [J]. Am J Hum Genet, 2000, 67(2) :383-394.
  • 8Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms,[J]. Nature, 2001, 409 (6822) : 928-933.
  • 9Lopez-Parra AM, Borobia AM, Baeza C,et al.A multiplex as say to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism [J]. Clin Biochem, 2013, 46(1-2):167-169.
  • 10Westaway K, Cruickshank M, Roberts GW, et al. Factors in- fluencing voer-anticoagulation and bleeding in warfarin therapy during the initial five months of treatment[J]. Aust Nuts J,2010,17(10) :28-31.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部